Sachdeva Rahul, Girshin Kristin, Shirkhani Yousef, Gad Parag
SpineX Inc, Los Angeles, CA, 91324, USA.
Department of Medicine, International Collaboration On Repair Discoveries (ICORD), University of British Columbia, Vancouver, BC, V5Z1M9, Canada.
Bioelectron Med. 2024 Jan 3;10(1):1. doi: 10.1186/s42234-023-00133-2.
Regaining motor function in individuals with cerebral palsy (CP) has been predominantly studied in children, resulting in an underrepresentation of adults in research efforts. We tested the efficacy of noninvasive spinal neuromodulation with neurorehabilitation (Spinal Cord Innovation in Pediatrics; SCiP™ therapy). A 60-year-old CP participant underwent 8 weeks of SCiP™ therapy, resulting in significant motor recovery measured by 14.2-points increase in gross motor function measure (GMFM-88) score, ~ three times the Minimal Clinically Important Difference (MCID) of 5-points. This represented gains in kneeling, sitting, and walking functions. The improvement in GMFM-88 score was maintained above the MCID at the follow up visit (10.3 points above the baseline), twenty weeks following the last therapy session, indicating a persistent effect of the therapy. Our preliminary findings support the therapeutic promise of SCiP™ therapy for enhancing motor function in CP adults. Broader investigations are needed to establish its wider applicability.
脑性瘫痪(CP)患者运动功能恢复的研究主要集中在儿童群体,导致成人在这方面的研究较少。我们测试了无创脊髓神经调节联合神经康复治疗(儿科脊髓创新疗法;SCiP™疗法)的疗效。一名60岁的CP患者接受了为期8周的SCiP™疗法,结果显示粗大运动功能测量量表(GMFM-88)得分显著提高了14.2分,这一改善幅度约为最小临床重要差异(MCID)(5分)的三倍,体现在跪、坐和行走功能的提升上。在最后一次治疗 session 后的二十周随访中,GMFM-88得分的改善仍维持在高于MCID的水平(比基线高10.3分),表明该疗法具有持续效果。我们的初步研究结果支持了SCiP™疗法在增强CP成人运动功能方面的治疗前景。需要进行更广泛的研究以确定其更广泛的适用性。